Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy

• G. L. Banna ^[4] ; R. Di Quattro ^[1] ; L. Malatino ^[1] ; G. Fornarini ^[2] ; A. Addeo ^[5] ; M. Maruzzo ^[6] ; V. Urzia ^[1] ; F. Rundo ^[7] ; H. Lipari ^[4] ; U. De Giorgi ^[3] ; U. Basso ^[6]
  1. [1] University of Catania

     University of Catania

     Catania, Italia

     
  2. [2] Ospedale San Martino

     Ospedale San Martino

     Genoa, Italia

     
  3. [3] Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

     Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

     Meldola, Italia

     
  4. [4] Division of Medical Oncology, Cannizzaro Hospital, Catania, Italy
  5. [5] Oncology Department, Geneva University Hospital, Geneva, Switzerland
  6. [6] Medical Oncology Unit 1, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy
  7. [7] STMicroelectronics ADG Central R&D, Catania, Italy

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 22, Nº. 11, 2020, págs. 2130-2135
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • PurposeTo identify patients with metastatic urothelial cancer (mUC) unlikely to benefit from immune-checkpoint inhibi-tors (ICIs).Methods/PatientsWe explored the predictive and prognostic values of baseline neutrophil-to-lymphocyte ratio (NLR), with cut-offs ≥ 3 and ≥ 5, and of a urothelial immune prognostic index (UIPI, based on increased NLR and LDH), on 146 patients.Results NLR and UIPI significantly predicted progressive disease and progression-free survival with both cut-offs (p = 0.0069, p = 0.0034, p = 0.0160, p = 0.0063; p < 0.001, p = 0.021, p = 0.014, p = 0.026; for NLR-3, NLR-5, UIPI-3, UIPI-5, respectively) and overall survival when NLR cut-off was ≥ 5 (p = 0.03 and p = 0.024, for NLR-5 and UIPI-5, respectively).ConclusionsNLR-5 deserves prospective validation to identify mUC patients with poor prognosis following ICIs.